Rezolute (RZLT) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Rezolute (RZLT) has outperformed ARS Pharmaceuticals (SPRY) over the past year, losing 50.0% versus a loss of 59.0%. Over five years, RZLT leads with a -34.1% price change compared with -55.8% for SPRY. ARS Pharmaceuticals is the larger company by market cap ($453.5 million vs $448.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RZLT | SPRY |
|---|---|---|
| Share price | $4.64 | $4.56 |
| Market cap | $448.79M | $453.48M |
| 1-day change | +5.94% | +4.59% |
| YTD return | +85.59% | -60.86% |
| 1-year return | -50.00% | -58.96% |
| 5-year return | -34.14% | -55.78% |
| EPS (TTM) | $-0.75 | $-2.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.46 | $13.15 |
| 52-week low | $1.07 | $3.99 |
| Distance from 52-week high | -59.50% | -65.32% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +111.21% | +393.42% |
| Average volume | 1.48M | 1.85M |
| Shares outstanding | 96.72M | 99.45M |
| Employees | 58 | 195 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Rezolute in Healthcare and ARS Pharmaceuticals in Health Care.
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Healthcare · Biotechnology · 58 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Health Care · Biotechnology: Pharmaceutical Preparations · 195 employees
RZLT vs SPRY FAQ
Which is bigger, Rezolute or ARS Pharmaceuticals?
ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $453.48M compared with $448.79M for Rezolute (RZLT).
Which stock has performed better over the past year, RZLT or SPRY?
RZLT returned -50.00% over the past 12 months, compared with -58.96% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are Rezolute and ARS Pharmaceuticals in the same industry?
No. Rezolute is in the Healthcare sector, while ARS Pharmaceuticals is in Health Care.